Verve Graham Number from 2010 to 2024

VERV Stock  USD 4.60  0.05  1.10%   
Verve Therapeutics Graham Number yearly trend continues to be fairly stable with very little volatility. Graham Number is likely to outpace its year average in 2024. During the period from 2010 to 2024, Verve Therapeutics Graham Number regression line of quarterly data had mean square error of  41.96 and geometric mean of  4.02. View All Fundamentals
 
Graham Number  
First Reported
2010-12-31
Previous Quarter
25.5981505
Current Value
26.88
Quarterly Volatility
10.39003714
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Verve Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verve Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 22.4 M, Interest Income of 8.3 M or Depreciation And Amortization of 3.3 M, as well as many indicators such as Price To Sales Ratio of 72.28, Dividend Yield of 0.0 or PTB Ratio of 1.57. Verve financial statements analysis is a perfect complement when working with Verve Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Verve Therapeutics Correlation against competitors.
For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.

Latest Verve Therapeutics' Graham Number Growth Pattern

Below is the plot of the Graham Number of Verve Therapeutics over the last few years. It is Verve Therapeutics' Graham Number historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Verve Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Graham Number10 Years Trend
Slightly volatile
   Graham Number   
       Timeline  

Verve Graham Number Regression Statistics

Arithmetic Mean8.18
Geometric Mean4.02
Coefficient Of Variation126.97
Mean Deviation8.76
Median1.90
Standard Deviation10.39
Sample Variance107.95
Range24.9828
R-Value0.80
Mean Square Error41.96
R-Squared0.64
Significance0.0003
Slope1.86
Total Sum of Squares1,511

Verve Graham Number History

2024 26.88
2023 25.6
2022 25.85
2021 20.13
2020 5.31

About Verve Therapeutics Financial Statements

Verve Therapeutics investors use historical fundamental indicators, such as Verve Therapeutics' Graham Number, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Verve Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Graham Number 25.60  26.88 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Verve Stock Analysis

When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.